Considering new lessons about the use of IL-6 inhibitors in arthritis

Takeuchi, Tsutomu, Smolen, Josef S., Choy, Ernest ORCID: https://orcid.org/0000-0003-4459-8609, Aletaha, Daniel, McInnes, Iain and Jones, Simon ORCID: https://orcid.org/0000-0001-7297-9711 2019. Considering new lessons about the use of IL-6 inhibitors in arthritis. BMJ Considerations in Medicine 2 (1) , pp. 7-11. 10.1136/conmed-2018-000002

Full text not available from this repository.

Abstract

Interleukin (IL)−6 represents one of several possible targets for the treatment of rheumatoid arthritis. Drugs targeting IL-6 can be divided into monoclonal antibodies against IL-6 itself and monoclonal antibodies against the IL-6 receptor. Both types of agent inhibit both classical signalling through membrane-bound IL-6 receptor, and trans-signalling via formation of a complex between IL-6 and soluble IL-6 receptor. The IL-6 receptor blockers tocilizumab and sarilumab inhibit the low affinity binding of IL-6 to its receptor. The anti-IL-6 agents clazakizumab and vobarilizumab also block binding of IL-6 to the receptor, while olokizumab blocks the higher affinity interaction of the IL-6-receptor complex with gp130. The doses and dosing intervals of the biologics targeting different elements vary, but no major differences in efficacy or safety have yet been seen between the two approaches, although more studies are needed in this area. In addition to the different blocking actions of monoclonal antibodies, we consider therapeutic strategies including the timing of IL-6 blockade and the use of monotherapy versus the addition of methotrexate.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine Systems Immunity Research Institute (SIURI)
Subjects:	R Medicine > R Medicine (General)
ISSN:	2515-3927
Related URLs:	https://considerations.bmj.com/content/2...
Date of Acceptance:	31 May 2018
Last Modified:	26 Nov 2022 13:22
URI:	https://orca.cardiff.ac.uk/id/eprint/131159

Actions (repository staff only)

Edit Item